Abrocitinib combined with low-dose corticosteroids in the management of tattoo-related cutaneous sarcoidosis: a case report.

Abstract

Purpose: Sarcoidosis is a chronic, multisystem granulomatous disorder characterized histologically by non-caseating granulomas. Despite the availability of various therapeutic options, long-term disease control remains a significant clinical challenge.

Materials and methods: We report the case of a 55-year-old female diagnosed with sarcoidosis. Skin and lymph node biopsies revealed non-caseating granulomatous inflammation, and chest CT indicated pulmonary involvement. Infectious causes of granulomatous disease, including Mycobacterium tuberculosis, non-tuberculous mycobacteria, and fungal infections, were excluded through com-prehensive testing. The patient initially received conventional systemic corticosteroid therapy but developed treatment-related complications. Due to the need for sustained disease control, an alternative regimen combining low-dose corticosteroids with the selective JAK1 inhibitor abrocitinib was initiated.

Results: The patient showed significant clinical improvement following the combination therapy, with no observed treatment-related adverse events.

Conclusions: This case suggests that low-dose corticosteroids combined with a JAK1 inhibitor such as abrocitinib may represent a treatment option for patients with sarcoidosis.